Teknova Launches Latest Proprietary AAV-Tek™ Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process Development
27 Setembro 2023 - 9:00AM
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer
of critical reagents for the research, discovery, development, and
commercialization of novel therapies, vaccines, and molecular
diagnostics, today launched the latest serotype-specific version of
their proprietary AAV-Tek™ AEX Buffer Screening Kit for AAV6,
along with a suite of reagents to support every step of the plasmid
production workflow. All products are available for purchase
starting today.
“Our team is relentlessly focused on developing solutions that
specifically address the needs of our customers. Our latest
products demonstrate our focus on addressing key bioprocessing
bottlenecks and manufacturing inefficiencies during process
development,” said Stephen Gunstream, Teknova’s President and Chief
Executive Officer. “We’re committed to fulfilling our goal of
becoming a true single-source partner for our customers across
multiple AAV gene therapy constructs and related industry
workflows. With today’s launch of our AAV-Tek AEX Buffer Screening
Kit for AAV6, we now support three different serotypes (including
AAV2 and AAV8) during downstream processing, with more to come. In
addition, we offer more than 60 off-the-shelf reagents to help
expedite plasmid production and purification. By making it fast and
easy to get the exact solution they need at every step along the
way, our customers are able to focus on the science and get into
the clinic faster.”
The first-of-its-kind AAV-Tek AEX Buffer Screening Kit helps AAV
gene therapy developers identify the ideal buffer formulation for
use during AAV downstream processing, specifically during the anion
exchange (AEX) purification step. Available for AAV2, AAV8 – and
now AAV6 – Teknova rigorously tested each serotype-specific version
of the kit with a robust design of experiments approach that
included hundreds of runs and validation against four critical
quality attributes: infectivity, recovery, purity, and peak
separation. Every version of the kit includes a unique selection of
serotype-specific equilibration and elution buffers designed to
optimize the separation of empty and full capsids during polishing
and can save AAV gene therapy developers months of process
development time.
Teknova is also introducing an extensive suite of high-quality
off-the-shelf reagents to support the end-to-end plasmid workflow
process, from culture media to buffers and reagents for use
throughout the pDNA growth and purification process. With solutions
available for selection and culturing, as well as purification and
recovery, Teknova has more than 60 existing formulations to help
customers expedite plasmid production to ensure reproducibility and
scalability throughout the discovery and commercialization
process.
Through the combination of new, proprietary products alongside
off-the-shelf reagents that enable bioprocessing workflows, Teknova
continues to be uniquely positioned as a multi-platform,
single-source partner for customers in cell and gene therapy,
molecular diagnostics, and synthetic biology, particularly as they
scale from process development to clinical-stage production.
The AAV-Tek AEX Buffer Screening Kit for AAV6 is available today
for purchase via phone, email, or online, and is priced at $1,400.
Teknova continues to work on additional serotypes to support AAV5
and AAV9, for release in the coming months.
For more information about the AAV-Tek AEX Buffer Screening Kit
or to purchase it online, visit http://www.teknova.com/AAV6.
For more information about the suite of plasmid workflow
solutions or to purchase them online, visit
http://www.teknova.com/plasmid-workflow.
ABOUT TEKNOVATeknova makes solutions possible.
Since 1996, Teknova has been innovating the manufacture of critical
reagents for the life sciences industry to accelerate the discovery
and development of novel therapies that will help people live
longer, healthier lives. We offer fully customizable solutions for
every stage of the workflow, supporting industry leaders in cell
and gene therapy, molecular diagnostics, and synthetic biology. Our
fast turnaround of high-quality agar plates, microbial culture
media, buffers and reagents, and water helps our customers scale
seamlessly from RUO to GMP. Headquartered in Hollister, California,
with over 200,000 square feet of state-of-the-art facilities,
Teknova’s modular manufacturing platform was designed by our team
of scientists, engineers, and quality control experts to
efficiently produce the foundational ingredients for the discovery
and commercialization of novel therapies.
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Alpha Teknova (NASDAQ:TKNO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Alpha Teknova (NASDAQ:TKNO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024